Subcutaneous infliximab in a young obese patient with Crohn's disease

Abstract

Idiopathic intestinal inflammation and obesity share an increasing trend in incidence and prevalence. Despite significant advances in pharmacological treatments, including targeted biological therapies, a significant proportion of patients with idiopathic intestinal inflammation experience treatment failure in the induction or maintenance phase.

Keywords

• Idiopathic intestinal inflammation
• Crohn's disease
• perianal disease
• biological therapy
• subcutaneous infliximab
• obesity